A recently published clinical trial on major depressive disorders out of the School of Psychology and Exercise Science at Murdoch University (Perth, Australia) reported that high absorption of BCM-95® Curcumin was significantly more effective in improving depression symptoms compared to that of a placebo.
The randomized, double-blind, placebo controlled study was published in the June 2014 Journal of Affective Disorders, with up to 56 individuals diagnosed with major depressive disorder treated with BCM-95® Curcumin (500 mg twice daily) or placebo for eight weeks. By week four, continuing through week eight, BCM-95 Curcumin was significantly more effective than placebo in lowering self-reported depressive and anxiety symptoms.
Additionally reported, when examining the effects of Curcumin in people with atypical depression, which is generally more difficult to treat, BCM-95 Curcumin had even greater antidepressant and anti-anxiety efficacy compared to placebo.
“There is now increasing support for the antidepressant effects of curcumin, with a previous study demonstrating BCM-95 curcumin to be as effective as a pharmaceutical antidepressant for the treatment of depression,” said Dr. Adrian Lopresti, lead author of the study. “Further larger clinical trials are required to determine the optimal treatment dosage, length of treatment and long-term efficacy of curcumin.”
It is important to note that the form of curcumin used in the study, BCM-95 Curcumin, has unique specifications, including high absorption and inclusion of turmeric essential oil, which is not found in standard curcumin and results may not apply to other forms of curcumin.
For more information, visit www.bcm95.com